Antibody-drug conjugates (also known as “immunoconjugates”) have only recently entered
the arsenal of anticancer drugs, but the number of undergoing clinical trials including them is
ever increasing and most therapeutic antibodies are now patented including their potential
immunoconjugate derivatives. They typically consist of three components: antibody, linker,
and cytotoxin. An antibody or antibody fragment targeted to a tumor-associated antigen acts
as a carrier for drug delivery and can be conjugated by cleavable or uncleavable linkers to a …